Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication
The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc.Ā lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy (PML). According to the National Institute of Neurological Disorders and Stroke, PML affects the white matter of the brain usually through a virus known as Polyomavirus JC (JC…